Table 2.
Univariate analysis of the prognostic factors of DFS in patients with stage II/III gastric cancer.
| Factors | Median Survival (Month) |
95% Confidence Interval | 3-Year DFS (%) | 5-Year DFS (%) |
p Value |
|---|---|---|---|---|---|
| Age (year) | 0.748 | ||||
| ≤65 (n = 935) | 46.7 | 32.7–60.8 | 52.6 | 46.9 | |
| >65 (n = 978) | 42.8 | 26.1–59.4 | 52.5 | 46.6 | |
| Sex | 0.417 | ||||
| Male (n = 1186) | 41.0 | 30.8–51.2 | 51.4 | 45.6 | |
| Female (n = 727) | 50.3 | 28.1–72.5 | 54.3 | 48.6 | |
| Location | <0.001 | ||||
| Upper (n = 382) | 46.2 | 0.1–98.9 | 52.0 | 47.9 | |
| Middle (n = 344) | 148.4 | NA | 60.4 | 53.4 | |
| Lower (n = 1119) | 42.6 | 32.1–53.0 | 51.7 | 45.6 | |
| Entire (n = 56) | 18.1 | 12.6–23.6 | 31.1 | 26.4 | |
| Other (n = 12) | 10.5 | 3.5–17.5 | 13.3 | 13.3 | |
| Type of gastrectomy | <0.001 | ||||
| Total (n = 608) | 28.0 | 18.6–37.3 | 47.2 | 41.8 | |
| Partial (n = 1305) | 55.0 | 31.6–78.5 | 55.0 | 49.0 | |
| Tumor size (cm) | <0.001 | ||||
| ≤2.4 (n = 258) | NA | 72.7 | 65.5 | ||
| 24.1–3.9 (n = 485) | 122.9 | NA | 59.5 | 52.6 | |
| 3.91–9.4 (n = 1006) | 30.2 | 24.2–36.2 | 47.2 | 42.1 | |
| >9.4 (n = 164) | 14.2 | 8.8–19.6 | 32.0 | 27.7 | |
| T status | <0.001 | ||||
| T1 (n = 64) | NA | 67.3 | 61.9 | ||
| T2 (n = 164) | NA | 74.7 | 65.4 | ||
| T3 (n = 382) | NA | 58.6 | 53.5 | ||
| T4a (n = 1161) | 34.2 | 26.7–41.7 | 49.2 | 43.4 | |
| T4b (n = 142) | 14.0 | 9.6–18.4 | 30.9 | 27.5 | |
| N status | <0.001 | ||||
| N0 (n = 332) | NA | 83.8 | 79.3 | ||
| N1 (n = 308) | NA | 68.8 | 63.1 | ||
| N2 (n = 459) | 139.9 | NA | 58.9 | 53.8 | |
| N3a (n = 494) | 21.8 | 18.9–24.7 | 34.1 | 27.2 | |
| N3b (n = 320) | 11.0 | 9.5–12.4 | 21.6 | 14.9 | |
| Stage (AJCC eighth edition) | <0.001 | ||||
| IIA (n = 203) | NA | 85.0 | 80.5 | ||
| IIB (n = 357) | NA | 75.9 | 69.4 | ||
| IIIA (n = 548) | 165.1 | NA | 60.1 | 55.0 | |
| IIIB (n = 454) | 21.9 | 18.9–24.8 | 34.0 | 28.1 | |
| IIIC (n = 351) | 11.5 | 10.1–12.8 | 20.6 | 14.2 | |
| LN ratio | <0.001 | ||||
| ≤0.05 (n = 566) | NA | 79.4 | 75.2 | ||
| 0.051–0.15 (n = 401) | NA | 62.3 | 56.6 | ||
| 0.151–0.37 (n = 479) | 26.9 | 23.2–30.5 | 42.5 | 34.6 | |
| 0.371–0.53 (n = 217) | 16.1 | 12.6–19.5 | 28.3 | 22.2 | |
| >0.53 (n = 250) | 9.9 | 8.4–11.4 | 14.3 | 8.8 | |
| Histological type | <0.001 | ||||
| Differentiated (n = 710) | 119.4 | NA | 58.9 | 53.6 | |
| Undifferentiated (n = 1203) | 31.9 | 25.0–38.9 | 48.7 | 42.6 | |
| Lymphatic invasion | <0.001 | ||||
| No (n = 650) | NA | 21.1–27.2 | 73.2 | 68.2 | |
| Yes (n = 1263) | 24.1 | 33.3–54.6 | 41.7 | 35.5 | |
| Vascular invasion | <0.001 | ||||
| No (n = 1577) | 59.7 | 15.0–104.4 | 55.9 | 50.0 | |
| Yes (n = 336) | 18.3 | 14.9–21.8 | 36.3 | 31.1 | |
| Perineural invasion | <0.001 | ||||
| No (n = 820) | NA | 64.4 | 59.7 | ||
| Yes (n = 1093) | 26.4 | 23.0–29.8 | 43.4 | 36.7 | |
| Chemotherapy | 0.571 | ||||
| No (n = 512) | 59.3 | NA | 56.0 | 49.7 | |
| Yes (n = 1401) | 41.4 | 31.4–51.3 | 51.5 | 45.9 |
AJCC—American Joint Committee on Cancer; DFS—disease-free survival; LN ratio—metastatic to examined lymph node ratio; NA—not available.